To understand what that means for safety, see the treatment options section
Critical Reviews in Food Science and Nutrition, 64 (10), 31393150
For example: A meta-analysis of 76 randomized trials found that use of GLP-1 receptor agonists (the drug class Ozempic belongs to) raises the risk of gallbladder and biliary diseasesespecially at higher doses or over longer durationswith relative risks ranging from 1.27 to 1.55 depending on the condition
Furthermore, exenatide enhanced the expression of phosphorylated ERK and M2-type microglial markers, demonstrating its neuroprotective and anti-inflammatory effects
Recent pharmaceutical interventions, especially GLP-1RAs, have advanced treatment for glycemic control and obesity
However, to impact macro-vascular disease, the drug chosen to lower blood glucose concentration may be more important [6]